We are live on
!
Find out more
KAM
Krensavage Asset Management Portfolio holdings
AUM
$256M
1-Year Est. Return
69.63%
This Fund
S&P 500
This Quarter
Est. Return
+6.37%
1 Year Est. Return
+69.63%
3 Year Est. Return
+113.28%
5 Year Est. Return
+196.5%
10 Year Est. Return
+463.27%
AUM
$178M
AUM Growth
-$39.3M
(-18%)
Cap. Flow
-$48.8M
Cap. Flow
% of AUM
-27.32%
Top 10 Holdings %
Top 10 Hldgs %
98.57%
Holding
14
New
1
Increased
3
Reduced
9
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Indivior Pharmaceuticals
INDV
|
+$8.22M |
| 2 |
Enanta Pharmaceuticals
ENTA
|
+$3.23M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
+$129K |
| 4 |
MURA
Mural Oncology
MURA
|
+$2.64K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TARO
Taro Pharmaceutical Industries Ltd.
TARO
|
+$28M |
| 2 |
Exelixis
EXEL
|
+$9.84M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$8.35M |
| 4 |
United Therapeutics
UTHR
|
+$6.04M |
| 5 |
BioNTech
BNTX
|
+$3.56M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
United Therapeutics
UTHR
$25.8B
| $36M | 20.15% |
100,332
-17,876
| -15% | -$6.04M |
|
|
2
Exelixis
EXEL
$13.3B
| $33.3M | 18.64% |
1,281,612
-395,781
| -24% | -$9.84M |
|
3
Cardinal Health
CAH
$53.9B
| $23.2M | 13.02% |
210,263
-7,393
| -3% | -$773K |
|
4
Biogen
BIIB
$30B
| $22M | 12.33% |
113,502
-10,283
| -8% | -$2.15M |
|
|
5
Enanta Pharmaceuticals
ENTA
$366M
| $15.5M | 8.7% |
1,498,074
+246,736
| +20% | +$3.23M |
|
|
6
Jazz Pharmaceuticals
JAZZ
$15.9B
| $12.3M | 6.88% |
110,257
+1,181
| +1% | +$129K |
|
|
7
BioNTech
BNTX
$22.9B
| $11.1M | 6.23% |
93,583
-38,710
| -29% | -$3.56M |
|
8
Sanofi
SNY
$103B
| $8.66M | 4.85% |
150,205
-3,627
| -2% | -$196K |
|
9
Alkermes
ALKS
$8.22B
| $7.04M | 3.94% |
251,495
-6,059
| -2% | -$162K |
|
|
10
Indivior Pharmaceuticals
INDV
$4.73B
| $6.84M | 3.83% |
+701,873
| New | +$8.22M |
|
11
Vanda Pharmaceuticals
VNDA
$307M
| $1.95M | 1.09% |
414,684
-247,482
| -37% | -$1.33M |
|
|
12
Regeneron Pharmaceuticals
REGN
$78.5B
| $371K | 0.21% |
353
-7,500
| -96% | -$8.35M |
|
|
MURA
13
DELISTED
Mural Oncology
MURA
| $237K | 0.13% |
75,868
+811
| +1% | +$2.64K |
|
|
TARO
14
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
| – | – |
-650,089
| Closed | -$28M |
|
Similar funds
CIA
2
CIM
JFG
PIP
LRIC
GAMC
TIA
Krensavage Asset Management's Q3 2024 Portfolio in Review
As of Q3 2024, Krensavage Asset Management held 14 positions worth $178M, down 18% from $218M the previous quarter. Its ten largest holdings account for 99% of the portfolio.
Krensavage Asset Management withdrew a net $48.8M in Q3 2024, closing 1 position and reducing 9 holdings. Its most notable exit was Taro Pharmaceutical Industries Ltd., an estimated $28M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Krensavage Asset Management opened a new position in Indivior Pharmaceuticals worth $6.84M.
- Krensavage Asset Management's largest Q3 2024 buy was Indivior Pharmaceuticals: 701,873 shares worth $6.84M.
- Krensavage Asset Management added most to Enanta Pharmaceuticals in Q3 2024, an estimated $3.23M increase.
- Krensavage Asset Management's biggest Q3 2024 reduction was Exelixis, cutting an estimated $9.84M.
- Krensavage Asset Management fully exited Taro Pharmaceutical Industries Ltd. in Q3 2024, selling an estimated $28M.
- Krensavage Asset Management's ten largest holdings make up 99% of its $178M portfolio in Q3 2024.
- Krensavage Asset Management opened 1 new position and closed 1 in Q3 2024.
- Krensavage Asset Management's portfolio value fell 18% quarter-over-quarter to $178M.
Based on Krensavage Asset Management's 13F filing for Q3 2024, filed 15 Nov 2024.